Myriad Genetics, Inc. MYGN
At closeNov 4, 2026, 7:00 PM EST
After hours · Nov 4, 7:00 PM ET
- YTD
- -2.11%
- 1 year
- -6.81%
- Market cap
- 575.81M
- Revenue (ttm)
- 837.60M
- Profit margin
- -15.20%
- EPS (ttm)
- -1.17
- Shares out
- 91.30M
- Forward P/E
- 71.53
- YTD return
- -2.11%
- 1-year return
- -6.81%
- Volume
- 2.08M
- Avg volume
- 2.30M
- Open
- 6.09
- Previous close
- 6.04
- Day's range
- 5.90 – 6.20
- 52-week range
- 2.74 – 8.09
- Beta
- 1.89
- Analysts
- Buy
- Price target
- 19.41 (+222.5%)
1M +1.43 (+31.22%)
Key statistics
- Enterprise value
- 1.05B
- PEG ratio
- 0.00
- Price / sales
- 1.17
- Price / book
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.10%
- Free cash flow
- 11.76M
- Total cash
- 102.40M
- Total debt
- 140.30M
- Return on equity
- -17.15%
- Short % of float
- 8.31%
- 50-day average
- 13.32
- 200-day average
- 21.11
Analyst view
Consensus: buy
- Target (low)
- 11.00
- Target (mean)
- 19.41
- Target (high)
- 29.00
- Strong buy4
- Buy4
- Hold5
- Sell1
- Strong sell2
Next earnings
Consensus EPS estimate -0.06447.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2025 | Dec 1, 2024 | 0.03 | 0.03 | 0.00 | 0.00% |
| Nov 7, 2024 | Sep 1, 2024 | 0.02 | 0.06 | +0.04 | +200.00% |
| Aug 6, 2024 | Jun 1, 2024 | — | 0.05 | +0.06 | +600.00% |
| Feb 27, 2024 | Dec 1, 2023 | 0.02 | 0.04 | +0.02 | +100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 25, 2025 | Raymond James | reit | Outperform | Outperform |
| Feb 25, 2025 | UBS | main | Neutral | Neutral |
| Feb 12, 2025 | Craig-Hallum | init | — | Buy |
| Jan 30, 2025 | Piper Sandler | main | Neutral | Neutral |
| Jan 28, 2025 | Goldman Sachs | main | Buy | Buy |
| Jan 16, 2025 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- myriad.com
News
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates 
Myriad Genetics Q3 Earnings Call Highlights 
Myriad Genetics Q3 2026 Earnings Call Transcript 
Myriad Genetics Raises FY2026 Sales Guidance from $770.000M-$790.000M to $780.000M-$790.000M vs $777.921M Est 
Myriad Genetics Q3 Adj. EPS $(0.11) Beats $(0.20) Estimate, Sales $202.700M Beat $191.329M Estimate 
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives 
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences 
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Your note
Sign in to keep a note on MYGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANCONA MARGARET | Officer | Sale | Aug 20, 2024 | 79,366 |
| DAVIS MARK STEVEN | Director | Stock Award(Grant) | Dec 9, 2024 | 22,816 |
| DIAZ PAUL J | Chief Executive Officer | Sale | Oct 10, 2024 | 962,378 |
| DREISMANN HEINRICH | Director | Sale | Sep 8, 2024 | 121,648 |
| FOX JENNIFER LYNNE | Officer | Stock Award(Grant) | Sep 2, 2024 | 61,771 |
| KUMAR RASHMI | Director | Sale | Aug 18, 2024 | 77,392 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.47% | 15,907,593 | 170.69M | Dec 30, 2024 |
| Vanguard Group Inc | 11.63% | 10,591,043 | 113.64M | Dec 30, 2024 |
| Wellington Management Group, LLP | 6.60% | 6,004,598 | 64.43M | Dec 30, 2024 |
| State Street Corporation | 6.07% | 5,525,705 | 59.29M | Dec 30, 2024 |
| Millennium Management Llc | 4.77% | 4,345,196 | 46.62M | Dec 30, 2024 |
| Glenview Capital Management, Llc | 4.57% | 4,157,324 | 44.61M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 6.47% | 5,889,365 | 63.19M | Dec 30, 2024 |
| Vanguard Explorer Fund, Inc. | 3.51% | 3,193,902 | 34.27M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.97% | 2,701,054 | 28.98M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.66% | 2,417,661 | 25.94M | Dec 30, 2024 |
| Vanguard Small-Cap Index Fund | 2.37% | 2,157,138 | 23.15M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.08% | 1,892,409 | 20.31M | Dec 30, 2024 |